PharmNXT Biotech, a fast-growing biotechnology company specialising in sustainable single-use technologies (SUTs), has been named the ‘Top Emerging Biotech Company’ at the BioSpectrum India Excellence Awards 2025. The annual awards recognise organisations demonstrating exceptional innovation, resilience and leadership across India’s life sciences ecosystem.

The company is playing a significant role in India’s biotech transformation with its eco-friendly single-use bioprocessing systems that reduce water consumption by 70–87 percent compared to traditional stainless-steel systems. By eliminating the need for extensive cleaning and sterilisation, PharmNXT’s solutions not only conserve water but also improve process efficiency and sterility assurance.  

Ankush Kapoor, Founder & CEO, PharmNXT Biotech, said, “Biotechnology is often the unsung pillar of India’s life sciences revolution. I firmly believe that India’s aspiration of achieving a USD 300-billion bioeconomy by 2030 will be powered by biotech innovation. At PharmNXT, our mission is to strengthen India’s life sciences supply chains and enhance the sector’s resilience through scalable, sustainable, and indigenous bioprocessing solutions.”

Highlighting market momentum, Sachin Joshi, Founder and Managing Director, noted that the global single-use bioprocessing market is expected to reach USD 151.48 billion by 2034, growing at a CAGR of 16.27 percent from 2025.

“SUTs are not just a technological evolution; they represent a paradigm shift toward sustainability. By minimising resource usage and environmental impact, we are helping transform one of the most resource-intensive industries into a greener, more responsible ecosystem,” he added.

PharmNXT operates its flagship Ekuse facility in Chakan, Pune — an integrated manufacturing unit producing Made-in-India single-use bioprocessing systems for the pharmaceutical and biologics sectors.

Startups such as PharmNXT are playing a pivotal role in India’s rapidly expanding bioeconomy, which has grown from USD 10 billion in 2014 to USD 165.7 billion in 2024, with a national target of USD 300 billion by 2030.

Other winners at the ceremony included Roche Diagnostics India (Top Diagnostic Leader), Vanguard Diagnostics (Excellence in Diagnostics), and Serum Institute of India (Outstanding Contribution to the Biotech Ecosystem).